Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile

VernacularTitle:富马酸替诺福韦二吡呋酯对血脂影响的研究进展
Author: Yuanqin DUAN ¹ ; Peng HU
Author Information

1. 重庆医科大学附属第二医院感染科　教育部感染性疾病分子生物学重点实验室　重庆医科大学病毒性肝炎研究所，重庆　400010
Keywords: Hepatitis B virus; Blood lipid; Human immunodeficiency virus; Tenofovir disoproxil fumarate
From: Chinese Journal of Hepatology 2023;31(10):1103-1107
CountryChina
Language:Chinese
Abstract: Tenofovir disoproxil fumarate (TDF) is a novel nucleotide reverse transcriptase inhibitor that is mainly used to treat human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. In recent years, an increasing number of studies have demonstrated that TDF treatment can reduce blood lipid levels in patients with AIDS and chronic hepatitis B and has a close correlation with the severity of the disease and the occurrence of cardiovascular events. This article reviews the research progress on the effect of TDF on blood lipid profiles, with the aim of providing a basis for rational use of TDF.